BriaCell Therapeutics Corp. Warrant (BCTXZ)

• Market cap: $484K
• 1 day: -1.19%
• 5 days: 9.04%
• 1 month: -20.16%
• 3 months: -78.71%
• 6 months: -84.16%
• Year to date: -84.16%
• 1 year: -84.16%
• 5 years: -84.16%
• 10 years: -84.16%
• Sector: Healthcare
• Industry: Biotechnology

About: BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.

Employees: 12

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

49.42% more ownership

Funds ownership: 0% [Q1] → 49.42% (+49.42%) [Q2]